Pentixapharm Holding AGFRA:PTP -4.35%20 PS Ratio is 733.33 as of Jun. 29, 2026, which is 59% above its 10-year median of 462.17. GuruFocus rates FRA:PTP with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 935 Biotechnology companies, Pentixapharm Holding AG ranks worse than 95.19% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pentixapharm Holding AG's share price is €2.20.
Pentixapharm Holding AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00. Hence, Pentixapharm Holding AG's PS Ratio for today is 733.33.
The historical rank and industry rank for Pentixapharm Holding AG's PS Ratio or its related term are showing as below:
FRA:PTP'
s PS Ratio Range Over the Past 10 Years
Min: 133.4 Med: 462.17 Max: 856
Current: 733.33
During the past 5 years, Pentixapharm Holding AG's highest PS Ratio was 856.00. The lowest was 133.40. And the median was 462.17.
FRA:PTP's PS Ratio is ranked worse than 95.19% of 935
companies
in the Biotechnology industry
Industry Median: 9.29
vs FRA:PTP: 733.33
During the past 5 years, Pentixapharm Holding AG's highest 3-Year average Revenue per Share Growth Rate was 58.70% per year. The lowest was 35.70% per year. And the median was 47.20% per year.
Back to Basics: PS Ratio
Pentixapharm Holding AG (FRA:PTP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pentixapharm Holding AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pentixapharm Holding AG PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pentixapharm Holding AG's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pentixapharm Holding AG's Share Price of today is €2.20. Pentixapharm Holding AG's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pentixapharm Holding AG (FRA:PTP) has a PS Ratio of 733.33 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pentixapharm Holding AG and its competitors. This is 59% above median its historical median of 462.17. Over the past decade, Pentixapharm Holding AG's PS Ratio has ranged from 133.40 to 856.00. According to the industry distribution chart, Pentixapharm Holding AG ranks #890 out of 935 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Pentixapharm Holding AG's PS Ratio too high?
Pentixapharm Holding AG's current PS Ratio of 733.33 is 59% above median its 10-year median of 462.17. Over the past 10 years, this metric has ranged from a low of 133.40 to a high of 856.00. The Biotechnology industry median PS Ratio is 9.29. Pentixapharm Holding AG's value of 733.33 is 7793.8% above this industry median. Based on the distribution chart, Pentixapharm Holding AG ranks #890 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #890 out of 935 companies for PS Ratio. This places Pentixapharm Holding AG in the lower half of its industry. The industry median PS Ratio is 9.29. Pentixapharm Holding AG's value of 733.33 is 7793.8% above this benchmark. Historically, Pentixapharm Holding AG's own PS Ratio has ranged from 133.40 to 856.00 over the past decade. While the company's 10-year median is 462.17 vs. the industry median of 9.29, Pentixapharm Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.29, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pentixapharm Holding AG's current PS Ratio of 733.33 is 7793.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pentixapharm Holding AG and its competitors. For the Biotechnology industry, the median PS Ratio is 9.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pentixapharm Holding AG's current PS Ratio is 733.33, which is 59% above median its own 10-year median of 462.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current PS Ratio of 733.33. The current PS Ratio is 733.33, which is 59% above median its 10-year median of 462.17 and 7793.8% above the Biotechnology industry median of 9.29. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current PS Ratio is 733.33 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score
Get the complete analysis for FRA:PTP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PTP has been successfully added to your 
